On 9 December 2024, Luxembourg hosted the annual General Assembly of the Beneluxa Initiative, bringing together member states to review progress, exchange ideas, and plan for the future. The day was filled with presentations on ongoing activities, interactive workshops on key...
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Beneluxa General Assembly and Steering Committee Meeting – December 2024
Belgium and the Netherlands opt for individual negotiations after a joint assessment of gene therapy Hemgenix®
As in every joint reimbursement process, the involved countries Belgium and the Netherlands, assessed the eligibility of Hemgenix® for joint negotiations after the recently finalised joint Health Technology Assessment process. Hemgenix® is a one-shot therapy for the treatment of...
Belgium and the Netherlands complete joint HTA report on gene therapy Hemgenix®
Hemgenix® is a gene therapy product for the treatment of adults with severe and moderately severe haemophilia B, who have not developed inhibitors against factor IX. Cross-border consultations resulted in a scientific and budget impact analysis report, approved in both countries...